__timestamp | Amgen Inc. | Cytokinetics, Incorporated |
---|---|---|
Wednesday, January 1, 2014 | 4422000000 | 44426000 |
Thursday, January 1, 2015 | 4227000000 | 46398000 |
Friday, January 1, 2016 | 4162000000 | 59897000 |
Sunday, January 1, 2017 | 4069000000 | 90296000 |
Monday, January 1, 2018 | 4101000000 | 89135000 |
Tuesday, January 1, 2019 | 4356000000 | 86125000 |
Wednesday, January 1, 2020 | 6159000000 | 96951000 |
Friday, January 1, 2021 | 6454000000 | 159938000 |
Saturday, January 1, 2022 | 6406000000 | 240813000 |
Sunday, January 1, 2023 | 8415000000 | 330123000 |
Monday, January 1, 2024 | 12858000000 |
Unlocking the unknown
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Amgen Inc. and Cytokinetics, Incorporated have demonstrated contrasting approaches to managing their cost of revenue. From 2014 to 2023, Amgen's cost of revenue has surged by approximately 90%, reflecting its expansive growth and increased production capabilities. In contrast, Cytokinetics has seen a staggering increase of over 640% in the same period, albeit from a much smaller base, highlighting its aggressive scaling efforts.
Amgen's cost efficiency is evident as it maintains a relatively stable cost structure, with a mean cost of revenue around $5.3 billion. Meanwhile, Cytokinetics, with a mean of $124 million, showcases its rapid expansion phase. This analysis underscores the diverse strategies employed by these biotech giants in navigating the financial intricacies of the industry.
Comparing Cost of Revenue Efficiency: Johnson & Johnson vs Amgen Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Amgen Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amgen Inc. and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Viatris Inc. and Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Cytokinetics, Incorporated
Grifols, S.A. vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Cytokinetics, Incorporated and Amphastar Pharmaceuticals, Inc.'s Expenses
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored